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117Perspectives on conventional therapy in Crohn’s diseaseMethods: Telephone interviews with 96 gastroenterologists and a web survey of 1370 gastroen-
terologists identified 26 key questions. Ten questions were taken forward to the next stage
based on the opinion of an International Steering Committee. Draft answers to the questions
were prepared from available evidence following a literature search. The draft answers were
debated in national meetings of participating countries (n=36) and voted on using a standard
scoring system. Revised answers went forward to an international meeting and were debated
and voted on using the same methodology. Final answers were developed, based on evidence
and clinical experience of the participants.
Results: Evidence on corticosteroid and immunomodulator use such as dosage, timing and dura-
tion, choice of drug or regimen, and safety is scarce. Key points of the answers included the im-
portance of: identifying patients with poor prognosis; early intervention with optimal doses of
immunomodulators; avoiding prolonged or repetitive corticosteroid therapy; achieving cortico-
steroid-free remission; achieving a balance between clinical benefit and safety when intensify-
ing or prolonging therapy or combining different agents; re-evaluating therapy at appropriate
time points; and considering the role of biomarkers and mucosal healing.
Conclusions: The answers to 10 key questions were based on available evidence and clinical ex-
perience of programme participants. It is hoped they will be of practical use in everyday gastro-
enterology practice.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.1. Introduction
Crohn's disease is a chronic inflammatory bowel disorder
characterised by alternating periods of clinical remission
and relapse. Current management focuses on inducing and
maintaining clinical remission, and recent guidelines are
available from the European Crohn's and Colitis Organisation
(ECCO)1,2 and the American College of Gastroenterology.3
Corticosteroids and immunomodulators have been used for
decades in inflammatory bowel disease (IBD), including
Crohn's disease,4–6 and are recommended by the guidelines
across the spectrum of disease severity, while anti-tumour
necrosis factor (TNF) agents were introduced in the late
1990s.
High-quality data from controlled clinical trials are limit-
ed for corticosteroids and immunomodulators. Indeed, both
European and US guidelines acknowledge that many ques-
tions regarding best practice in the management of Crohn's
disease remain unanswered because of insufficient data,
and that treatment is often a matter of judgement and
best practice.2,3 Thus, guidelines give relatively little direc-
tion on the precise use of corticosteroids and immunomodu-
lators in terms of dosage, mode of administration and
duration of therapy. As a result of such uncertainties in the
guidelines, it therefore seems highly likely that physicians
involved in the day-to-day management of Crohn's disease
will have many questions about the best use of these conven-
tional therapies in their clinical practice.
An educational programme, ‘IBD Ahead 2010’, was estab-
lished to explore questions commonly raised by clinicians
about the optimal use of corticosteroids and immunomodu-
lators in the management of Crohn's disease. Gastroenterol-
ogists from many countries worldwide were actively involved
in the programme through market research activities and
discussions at national and international meetings. The
goal of the programme was to provide practical answers to
questions raised in everyday clinical practice, based on
available evidence and the clinical experience of pro-
gramme participants.2. Methods
A total of 36 countries worldwide participated in the pro-
gramme. It was overseen by an International Steering Com-
mittee (ISC) made up of 16 gastroenterology specialists
from Europe, Canada, Australia, Turkey and Japan (members
are listed in Acknowledgements). In addition, each partici-
pating country had its own National Steering Committee.
The ISC was chaired by two of the authors of the present
paper (J-FC and RP).
The programme took place between July 2009 and De-
cember 2010 and consisted of several stages (Fig. 1). Tele-
phone interviews were initially conducted with 96
gastroenterologists from nine countries (Belgium, Canada,
France, Germany, Italy, Netherlands, Spain, Sweden, UK)
to identify key unanswered questions in the routine use of
corticosteroids and immunomodulators in the treatment of
Crohn's disease. A total of 26 questions were identified and
fed into a web-based survey of 1370 gastroenterologists
who ranked the importance of each question. The results
from the web-based ranking were debated at a meeting of
the ISC held in November 2009, and agreement on which
questions the ISC considered to be the most important was
obtained via informal debate. In some cases, two or more
of the 26 questions were combined and a total of 10 ques-
tions went forward to the next stage.
Draft answers to the 10 questions were prepared by au-
thors of the present paper. PubMed and Embase were
searched using pre-defined search strings and limits, and ad-
ditional searches were conducted by hand as required. Ab-
stracts from the following conferences were searched:
American College of Gastroenterology, ECCO, Digestive Dis-
ease Week and United European Gastroenterology Week.
No time limits were included in the search criteria except
for conference abstracts, which were limited to 2007–
2009. National meetings were held to present the draft an-
swers to the National Steering Committee of 35 out of the
36 participating countries and other nationally-recognised
gastroenterologists. Participants voted on their level of
26 unanswered questions identified by market research (July-Aug 2009)
Web-based ranking of questions (Sept-Oct 2009)
Consolidation of questions (Nov 2009)
10 key questions selected by International Steering Committee based on ranking results
Literature search and development of draft answers (Dec 2009-Mar 2010)
National meetings (May-June 2010)
Draft answers and literature search presented and feedback on draft answers obtained
Feedback from national meetings consolidated by International Steering Committee
and revised answers prepared (July-Sept 2010)
International meeting (Sept 2010)
Consolidated answers presented to National Steering Committees and revised answers developed
Final answers and practical recommendations disseminated via meetings 
within participating countries (Oct-Dec 2010)
Figure 1 Overview of the programme.
118 M. Ferrante et al.agreement with each draft answer using a scale of 1 to 9
(where 1 = strong disagreement and 9 = strong agreement).
Each voting score was allocated to one of three ranges: 1–
3, 4–6 and 7–9. If ≥75% of participants scored within the
7–9 range, then the answer was deemed to be agreed
upon. If b75% of participants scored within this range, the
answer was debated and revised, and a second vote took
place. Again, if ≥75% of participants scored within the 7–9
range, the answer was deemed to be agreed upon. If agree-
ment was not reached at this stage, a lack of agreement was
noted. Similar methodology has been employed in develop-
ment of consensus-based guidelines in the UK.7,8 Feedback
from each country was consolidated into revised answers,
taking into account consistency between countries and al-
ternative views.
The revised answers were discussed and voted upon at an
international meeting attended by participants from 30 out
of the 36 participating countries; each country had one
vote per question. In each vote, the countries indicated
their level of support for the revised answer using the same
voting methodology as in the national meetings. This was
not a formal consensus or Delphi process; the voting aimed
to achieve answers on which all participants had reached
broad agreement. Notable differences between countries
were discussed at the international meeting. As in the na-
tional meetings, agreement on the answer was defined as
≥75% of participants scoring the answer within the 7–9
range on the scale.
3. Results and discussion
The results of the web-based survey are shown in Supple-
mentary Table 1. The questions and final answers agreedupon after voting at the international meeting are described
below. Agreement on answers was achieved for all 10 questions.
Question 1: Introduction of corticosteroids
1. When should we introduce corticosteroids, and for how long?
1. Systemic corticosteroids are best used for moderately to
severely active Crohn's disease of any location. Their use in
isolated perianal Crohn's disease is not supported.
2. Budesonide is preferred to systemic corticosteroids for
mildly to moderately active ileocaecal disease and right
colonic disease, but is not universally available. In countries
where budesonide is not available, early introduction of
immunomodulators (and/or anti-TNF therapy) for their
corticosteroid-sparing properties is appropriate.
3. The duration of initial treatment with systemic
corticosteroids at full dose depends on the response of the
patient. There is no clear evidence that continuing the full
dose (40–60 mg prednisone or equivalent) beyond weeks 1–3
influences remission rates. Patients who do not respond
within 2–4 weeks had best be further investigated and other
therapeutic options considered.
100% agreement after 2nd vote
The effect of systemic corticosteroids on remission induc-
tion in Crohn's disease has been studied in several uncon-
trolled and controlled trials. In a Cochrane systematic
review of controlled trials, systemic corticosteroids were
significantly more effective than placebo and 5-aminosa-
licylic acid (mesalamine, mesalazine).9 The clinical response
rate achieved in the studies varied from 60% to 97% over 1–
5 months in mildly to severely active disease of any location.
However, in fistulising perianal Crohn's disease, corticoste-
roids are ineffective10 and therefore their use in perianal
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disease.
Another Cochrane review has shown that budesonide is
significantly more effective than placebo or mesalamine in
short-term remission induction (within 8 weeks of treat-
ment) in moderately active Crohn's disease, but is less effec-
tive than systemic corticosteroids in severe disease
(characterised as Crohn's Disease Activity Index [CDAI]
N300).11 A recent randomised, double-blind, multicentre
trial has demonstrated equal efficacy of budesonide and
mesalamine, for induction of remission in mildly to moder-
ately active right-sided colonic Crohn's disease.12 If the re-
sults are confirmed in other studies, mesalamine may be an
alternative to budesonide in these patients. With regard to
its pharmacokinetic characteristics, it is important to em-
phasise that budesonide is only effective in Crohn's disease
located in the terminal ileum and/or proximal colon.13
The suggestion of an early introduction of immunomodu-
lators and/or anti-TNF agents where budesonide is unavail-
able is based on opinion, as no data are currently available
on the risk–benefit ratio of this approach. A multicentre,
randomised, open-label study comparing conventional treat-
ment (systemic corticosteroids followed by immunomodula-
tors in the case of relapse after corticosteroid-tapering)
versus early combined immunosuppression (three infusions
of infliximab and concomitant immunomodulators) showed
no difference in the corticosteroid-free remission rate be-
tween the two groups beyond 1 year.14 However, it is diffi-
cult to extrapolate these data to budesonide, as patients
who are candidates for budesonide therapy may have differ-
ent characteristics to those receiving systemic corticoste-
roids. Factors other than local availability of budesonide
(i.e. age, gender, disease phenotype and behaviour, possi-
bility of limited surgery) should be considered in the decision
to introduce immunomodulators and/or anti-TNFs as an
alternative to budesonide.
For remission induction in active Crohn's disease, most
studies of systemic corticosteroids have used a full dose
(40–60 mg prednisolone equivalent) for 1–3 weeks, followed
by different tapering regimens. Although one study from the
GETAID group showed a maximal clinical response rate at
week 7,15 the 18-month remission rate in the follow-up
study was only 34%.16 Thus, as the risk of side effects in-
creases with cumulative doses of corticosteroids, continuing
these drugs at full dose beyond 1–3 weeks does not appear
to be justified.
Question 2: Dosing strategy for corticosteroids
2. What is the best dosing strategy for the use of corticosteroids,
in terms of: starting and maximum doses, duration, dose
escalation/de-escalation (when? rate?), formulation, avoiding
side effects? What duration of corticosteroid treatment is
linked to the occurrence of side effects?
1. The optimal initial dose of oral systemic corticosteroids in
Crohn's disease ranges from 40 to 60 mg/day to 1 mg/kg/day.
For intravenous hydrocortisone, the optimal starting dose is
300–400 mg/day.
2. The optimal starting dose of budesonide is 9 mg/day.
3. Tapering of corticosteroids is generally initiated within a
week of starting therapy, and after no more than 3–4 weeks.There are no trials assessing different tapering regimens, and
‘standard’ regimens differ amongst centres. A reasonable
approach is to reduce the dose by 5 mg/week, tapering to
zero over 8 weeks (from an initial dose of 40 mg/day).
Treatment should not exceed 12 weeks except in exceptional
circumstances. Early introduction of immunomodulators or
anti-TNF therapy is appropriate.
4. No data are available to allow evaluation of any benefit of
intentional dose escalation of corticosteroids.
5. Systemic corticosteroids and budesonide are ineffective as
maintenance therapy. It is strongly recommended to taper all
corticosteroids to zero and switch appropriate patients to
immunomodulator (or anti-TNF) therapy.
6. Corticosteroids have been shown to increase the risk of
serious, opportunistic infections and mortality, both
independently or in combination with immunomodulators and
anti-TNF agents.
7. The best way to prevent corticosteroid-induced side effects
is to avoid prolonged or repetitive use and to switch
appropriate patients to immunomodulator therapy and/or
anti-TNF therapy. Surgery is an appropriate option for some
patients demonstrating corticosteroid dependency and could
be considered.
8. To prevent corticosteroid-induced loss of bone mineral
density, calcium and vitamin D supplements should be
provided. Clinicians treating with corticosteroids should
familiarise themselves with local guidelines in managing
corticosteroid-induced metabolic bone disease.
9. Not all corticosteroid-induced side effects occur dose- or
time-dependently.
94% agreement after 2nd vote
No formal dose–response trials have been performed with
systemic corticosteroids in Crohn's disease. The usual start-
ing dose for induction of remission in active Crohn's disease
is 40–60 mg prednisolone or equivalent. A higher starting
dose of 1 mg/kg seems to increase the short-term remission
rate (reviewed by Lichtenstein et al.17); however, no com-
parative studies have been performed. For budesonide, a
landmark placebo-controlled, randomised, double-blind
trial in active ileal or proximal colonic disease showed the
highest remission rate (51%) at 8 weeks with a dose of 9 mg
compared with doses of 3 and 15 mg.18
Only one study provides a head-to-head comparison of
two different systemic corticosteroid tapering regimens on
short- and medium-term (6 months) remission rates, showing
no difference between a 4-week versus a 12-week tapering
regimen.19 In addition, none of the various tapering regi-
mens used across different studies have resulted in more
favourable long-term outcomes. In general, the evidence
on dosing and tapering of corticosteroids is limited. There-
fore, the proposed tapering regimen and maximum treat-
ment duration of approximately 12 weeks for systemic
corticosteroids should be seen as opinion which achieves a
compromise between the maximum benefit on remission
rate and the risk of cumulative dose-related side effects.
For budesonide, the best efficacy in remission induction
has been achieved with a full 9 mg dose used over
8 weeks,18 with tapering thereafter.
No data are available on the utility of intentional dose es-
calation of corticosteroids when remission has not been
achieved. Regarding maintenance of remission, two
120 M. Ferrante et al.Cochrane reviews have concluded that systemic corticoste-
roids and budesonide are ineffective in this setting.20,21
It has been demonstrated that the use of corticosteroids
carries the risk of opportunistic infections22 and the risk ap-
pears to increase with dose and prolonged treatment.23
Early introduction of immunomodulators and/or anti-TNF
agents seems to be a reasonable approach to limit these com-
plications by facilitating corticosteroid withdrawal. However,
there is also a risk of infectious complications with immuno-
modulators and anti-TNF agents, which is increased with use
of multiple agents. Therefore, surgery may be considered in
patients in whom it is not possible to withdraw corticosteroids
in spite of immunomodulator and/or anti-TNF therapy.
The key to prevention of corticosteroid-induced loss of
bone mineral density (BMD) is limitation of the cumulative
dose of corticosteroids. No extensive evidence of any benefit
of vitamin D and calcium supplementation on BMD is avail-
able for patients with Crohn's disease receiving corticoste-
roids. Nevertheless, the recommendation of standard
supplementation of vitamin D and calcium is supported by
data in the healthy elderly showing a reduction of the risk
of fractures with this approach, together with demonstrated
vitamin D deficiency in Crohn's disease patients.24
Corticosteroid-related side effects can occur at any time
during treatment.1 Neuropsychiatric side effects, hyperten-
sion, cosmetic side effects (moon face, acne, hirsutism) as
well as pituitary axis suppression may occur as soon as within
2 weeks of starting therapy. Loss of BMD depends on the cu-
mulative dose of corticosteroids but may be manifested by
fractures as early as within 2 months of treatment. It is not
clear what duration of treatment is related to the develop-
ment of cataracts but seems to be at least 1 year in adults.
Question 3: Introduction of immunomodulators
3. How early should immunomodulators be introduced and
which regimen should be used?
1. Initiation of immunomodulators (±anti-TNF therapy) early
in the disease course (often within a week or two of diagnosis)
should be considered for patients with severe disease,
paediatric patients and for patients at high risk of progression
to disabling disease.
2. It is generally appropriate to start thiopurines or
methotrexate in immunomodulator-naïve patients who have a
relapse, are corticosteroid-dependent, or who need repeated
courses of corticosteroids. This may include patients who
need two or more courses of corticosteroids within 12 months;
who relapse as the corticosteroid dose is tapered below
15 mg; or who relapse within 3 months of stopping
corticosteroids. These limits are arbitrary, but serve as
guidance for clinical practice. The aim is to withdraw
corticosteroids completely.
3. Thiopurines are currently indicated for postoperative
prophylaxis immediately after surgical resection of
ileocolonic disease. This is true in patients with high risk of
recurrence; in the other patients thiopurines should be
introduced if there is evidence of recurrence at 6–12 months.
89% agreement after 2nd vote
Crohn's disease exhibits a wide phenotypic spectrum at
diagnosis, and becomes more disabling over time in aconsiderable proportion of patients, either through develop-
ment of complications such as abscesses, internal fistulae
and strictures, or as a result of cumulative structural dam-
age.25 Initiation of immunomodulators early in the disease
course—namely close to diagnosis—in patients already dem-
onstrating or at risk of complicated disease seems reason-
able since it may induce long-term corticosteroid-free
remission.5 Specifically, the goal should be induction of mu-
cosal healing and achievement of a symptom-free everyday
life, with minimal use of corticosteroids.14,26,27 Children
seem to benefit more from early initiation of immunomodu-
lators; indeed, children treated early with 6-mercaptopu-
rine (6-MP) showed a superior outcome compared with
those receiving placebo.28 However, recent data do not sup-
port any advantage of early initiation of azathioprine to in-
duce long-term corticosteroid-free remission in recently
diagnosed adult Crohn's disease.29
Clinical variables associated with a complicated disease
course (defined in most studies as the need for resection, pro-
gression towards stricturing or penetrating behaviour or devel-
opment of steroid dependency) include active smoking,
age less than 40 years, extensive length of affected digestive
tract, perianal lesions, extraintestinal manifestations, corti-
costeroid therapy during the first flare and perhaps persistent-
ly elevated C-reactive protein (CRP). Such variables have been
proposed as predictors of a worse prognosis in medically trea-
ted patients with Crohn's disease.30 Although these variables
have not been validated in adequately powered prospective
clinical trials, they do identify patients who would benefit
most from early aggressive therapy. ECCO guidelines propose
a series of (in certain cases, arbitrary) definitions to serve as
a guide for therapy decision-making: corticosteroid-refractory
and -dependent patients are indicated as the best candidates
for early treatment intensification.2
Most complications of Crohn's disease need surgical inter-
ventions that lead to more disabling disease. However, sur-
gery does not provide a cure, since the disease almost
invariably recurs close to the anastomosis. Postoperative re-
currence following ileocaecal resection for therapy-resistant
ileocolitis in Crohn's disease predominately occurs in the
pre-anastomotic area in the neoterminal ileum and pro-
gresses in a few years from aphthae to larger ulcers and
stricture; however, clinical symptoms can appear 2–3 years
after the development of early mucosal lesions.31 Azathio-
prine either as monotherapy or combined with a baseline
course of metronidazole is the agent of choice to prevent re-
currence in the postoperative setting based on prospective
evidence.32–34 However, azathioprine appears to be less ef-
fective in patients with severe endoscopic recurrence.35
Smoking, prior intestinal resection (including appendectomy),
penetrating disease behaviour prior to surgery, perianal
location and extensive small bowel resection have been
shown to predict early postoperative recurrence and thus
mandate an aggressive therapeutic approach immediately
after surgery. Low risk patients can be offered an endoscopy
at 6–12 months after surgery and treated according to endo-
scopic findings and clinical status.36,37
Nonetheless, the potential benefit of early initiation of
immunomodulators must be weighed against the possibility
of an increased risk of treatment-emergent side effects
such as more frequent infections or a higher rate of
malignancies.
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4. What is the best dosing strategy for immunomodulators, in
terms of: starting and maximum doses, duration, dose
escalation/de-escalation (when? rate?), which
immunomodulator first?
1. The most effective doses appear to be 2.0–3.0 mg/kg/day
for azathioprine and 1.0–1.5 mg/kg/day for mercaptopurine.
Initial dose strategies in common practice are either a gradual
dose increase starting with 50 mg parenteral azathioprine
(25 mg mercaptopurine) or full dose therapy with prior
determination of thiopurine methyltransferase (TPMT)
activity/genotype.
2. For methotrexate, the dosing strategy best supported by
evidence from clinical trials is 25 mg per week for 8–12 weeks
and 15 mg per week for maintenance.
3. Azathioprine is generally used as a first-line
immunomodulator.
4. Azathioprine/mercaptopurine treatment is best
maintained for several years because of the high relapse rates
in patients with Crohn's disease when these drugs are
discontinued.
93% agreement after 2nd vote
Both thiopurine drugs, azathioprine and 6-MP, are effec-
tive, corticosteroid-sparing immunomodulators for the in-
duction (although their onset of action is slow) and
maintenance of pre- and postoperative remission in luminal
Crohn's disease. The most effective doses appear to be
2.0–3.0 mg/kg for azathioprine and 1.0–1.5 mg/kg for 6-
MP when administered orally. A trial evaluating whether
the onset of action could be accelerated found that a high
dose infusion given over 36 h was no more effective than
conventional oral dosing.38 Higher response rates have
been obtained with azathioprine than with 6-MP, and thus
azathioprine is generally preferred as a first-line immuno-
modulator therapy,39-41 although the only randomised con-
trolled trial evaluating 6-MP used a low dose.33 Future
studies should evaluate higher doses.
It has not yet been well determined how best to start ther-
apy: dose escalation to the weight-based dose versus starting
immediately at the weight-based dose (no randomised con-
trolled trials comparing the two strategies have been con-
ducted). There is more tertiary-centre evidence to support
the dose escalation method: azathioprine may be started at
50 mg daily and the dose increased by 25 mg every 1–
2 weeks to a target dose of 2.0–3.0 mg/kg/day along with
monitoring for leukopenia and other potential adverse events.
6-MP may be started at 25 mg daily and the dose increased by
25 mg every 1–2 weeks to a dose of 1.0–1.5 mg/kg/day, also
with monitoring.40 Azathioprine and 6-MP are prodrugs that
undergo extensive metabolism. TMPT has a major role in this
metabolism. Measurement of azathioprine and 6-MP metabo-
lites and TPMT activity in order to adjust dosage and avoid
side effects is not routinely performed since only 0.3% of the
general population demonstrate absent or extremely low
TPMT activity. However, where available, suchmeasurements
may be useful in guiding dose optimisation when remission has
not been achieved.42 Treatment with azathioprine and 6-MP
should be maintained for several years due to the high relapse
rate when these drugs are discontinued.43Methotrexate can be used as an alternative immunomod-
ulator, although its use is limited because of teratogenic ef-
fects during pregnancy, as well as an impractical route of
administration. Methotrexate is best administered intramus-
cularly or subcutaneously at a weekly dose of 25 mg for
16 weeks followed by a maintenance dose of 15 mg/week.
There are no randomised controlled trials comparing differ-
ent dosing regimens and routes of administration, although
oral methotrexate seems less efficacious. However, for
practical reasons oral dosing is more convenient and pre-
ferred by patients. No controlled data exist regarding the
optimal duration of methotrexate therapy.44,45
Question 5i: Monitoring efficacy
5(i). How should efficacy of a treatment be monitored clinically
and biologically? What is the definition of treatment failure?
When should the effect of treatment be evaluated?
1. Assess remission status/treatment success using clinical
signs and symptoms together with normal biological markers
(CRP, faecal calprotectin). Endoscopy and imaging techniques
can also be used to determine inflammation objectively or
when response to treatment is unclear. The CDAI and Harvey
Bradshaw Index can be used to quantify clinical efficacy,
although opinion differs regarding the relative utility of these
tools in everyday practice.
2. Assessment of azathioprine metabolite levels is useful in
making management decisions and to identify non-compliant
patients or assess non-responders.
3. Trough levels of anti-TNF agents may be useful for
identifying the cause of non-response.
4. Treatment failure may be defined after the appropriate
period of therapy as:
i. Lack of symptomatic response
ii. Lack of improvements in biological markers
iii. Lack of corticosteroid-free remission
iv. Inflammation, signs of mucosal ulceration with
endoscopy or imaging
5. Clinical response/treatment failure should be assessed at:
i. Thiopurines or methotrexate: not earlier than 3 months,
not later than a maximum period of 6 months
ii. Anti-TNFs: at a maximum period of 14 weeks (6–14 weeks)
after starting therapy
iii. If mucosal healing is to be assessed, this should be
performed between 6 and 12 months
79% agreement after 1st vote
Although the CDAI correlates poorly with healing of in-
flammation by corticosteroids,15 in the era of biologics and
immunomodulators it has been repeatedly shown to reflect
disease activity at the mucosal level, albeit imperfectly.46
There are similarly well-validated endoscopic scores for as-
sessment of Crohn's disease activity such as the Crohn's Dis-
ease Endoscopic Index of Severity47 and Simple Endoscopic
Score for Crohn's Disease.48 For fistulising disease, the pres-
ence of draining fistulae or the need for surgical intervention
is an appropriate endpoint to measure treatment failure and
is easily applied to clinical practice.49,50 A corticosteroid-
free remission seems the most clinically relevant endpoint51
as the CDAI is a cumbersome tool in a busy clinical environ-
ment. The Harvey Bradshaw Index may be a more practical
day-to-day tool.52
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cosal healing53 as well as being predictive of disease re-
sponse54 and relapse.55 However, it correlates less
accurately with the activity of small bowel Crohn's dis-
ease.53 Faecal biomarkers of inflammation such as calpro-
tectin and lactoferrin are superior to serum CRP in
diagnostic accuracy of intestinal inflammation.56 Faecal cal-
protectin concentrations correlate well with mucosal heal-
ing in adults and children57 and an elevated faecal
calprotectin is predictive of relapse in those with Crohn's dis-
ease in clinical remission.58 Thiopurine metabolite concen-
trations may help guide management decisions59 and the
measurement of trough infliximab and adalimumab concen-
trations may also provide insights into dosing and likelihood
of response and failure with these therapies.60,61
The timing of clinical assessment will depend on the phar-
macological agent. Immunomodulators such as azathioprine
and methotrexate may take 3–6 months to achieve full clin-
ical efficacy and mucosal healing.62 In the context of biolog-
ical agents, clinical responses can be seen much earlier and
assessment at 4–6 weeks has been suggested.51 Based on AC-
CENT II (A Crohn's Disease Clinical Trial Evaluating Infliximab
in a New Long-Term Treatment Regimen)50 and CHARM
(Crohn's trial of the fully Humanised Antibody Adalimumab
for Remission Maintenance),49 assessment for response to
treatment of fistulae should take place at weeks 6–14
after starting therapy.
In summary, no particular clinical or biological marker is
specific for treatment failure and no specific marker corre-
sponds to mucosal healing. In practice, clinical acumen, judi-
cious use of endoscopy and common laboratory monitoring
remain the gold standard of clinical care.
Question 5ii: Assessment of mucosal healing
5(ii). Should mucosal healing be assessed?
1. In the absence of a clinical indication, there is insufficient
evidence to recommend the routine assessment of mucosal
healing in clinical practice. The assessment of mucosal
healing may have a useful role in guiding treatment
adjustments.
85% agreement after 1st vote
It has been established that early mucosal healing re-
duces hospitalisation, long-term remission and need for ab-
dominal surgery,63 whilst lack of mucosal healing following
surgical resection is predictive of clinical relapse.31
Corticosteroids are effective in relieving symptoms in
Crohn's disease;4 however, even high-dose corticosteroids
induce complete mucosal healing in only 27% of patients.15
Azathioprine heals the mucosa in 36–70% of patients after
up to 3.5 years46 and is similarly effective following surgical
resection.64 Data on mucosal healing with methotrexate are
limited, with rates up to 37.5% reported.65 Maintenance bio-
logical therapy is more effective than episodic treatment in
achievement of mucosal healing. Early aggressive therapy
with azathioprine and infliximab in the SONIC (Study of Im-
munomodulator Naïve Patients in Crohn's Disease) trial
resulted in higher mucosal healing rates.66 Early mucosal
healing induced by biological agents predicts long-term
steroid-free remission26 and may also predict which patients
are able to stop immunomodulator therapy.67In summary, mucosal healing may be an attractive end-
point, but regular endoscopic assessment is impractical and
there is insufficient evidence to recommend it in the ab-
sence of a clinical indication. Although imperfect, non-
invasive markers such as faecal calprotectin have been
shown to predict mucosal healing and may be realistic alter-
natives.68 Other alternatives include assessment of mucosal
healing via magnetic resonance imaging or trans-abdominal
ultrasound.69,70
Question 6: Combination of azathioprine and an anti-TNF
agent
6. If azathioprine and an anti-TNF agent are given in combination,
should any of the treatment be stopped? Which treatment
should be stopped to achieve the smallest reduction in efficacy?
When should that treatment be stopped?
1. When using azathioprine with anti-TNF therapy, the
immunomodulator treatment must be individualised
according to the individual's treatment and disease status.
The benefits of long-term therapy must be weighed against
the potential risks for each patient:
i. If the patient hasmoderately active Crohn's disease and is
naïve to immunomodulator therapy, the combination of
immunomodulator and infliximab can improve rates of
corticosteroid-free remission for up to 1 year
ii. In a patient flaring despite immunomodulator therapy,
maintaining the combination of immunomodulator and
anti-TNF therapy beyond 6 months may offer no clinical
benefit, although this is disputable
iii. There is an increased risk of opportunistic infectionwith
long-term immunomodulator and anti-TNF therapy and of
malignancy with thiopurine therapy
iv. There is a small potential risk of hepatosplenic T cell
lymphoma (HSTCL) in young adults, particularly young
males, with a combination of azathioprine and infliximab
or adalimumab
86% agreement after 2nd vote
Apparently conflicting results of recent major clinical tri-
als have confused clinicians. In one study, induction and
maintenance therapy with methotrexate and infliximab
was shown to have no long-term advantage over infliximab
alone.71 Furthermore, although continuation of azathioprine
with infliximab for 2 years resulted in higher trough inflixi-
mab concentrations and lower CRP concentrations compared
with withdrawal of azathioprine treatment at 6 months, it
did not translate into clinical benefits or mucosal healing.72
Similar findings have been noted for adalimumab73 and cer-
tolizumab.74 Results from the SONIC trial are apparently at
odds with these findings, as the combination of azathioprine
and infliximab was found to be superior to infliximab alone
in achieving clinical response and mucosal healing in de
novo Crohn's disease.66 An important detail is that patients
recruited into SONIC were naïve to immunomodulatory and
biological therapy, and represent a different population to
the aforementioned studies; however, the findings have
been supported by a recent observational study.75 There
are no data on the effect of concomitant immunomodulator
withdrawal for certolizumab or adalimumab.
Balancing the very real risk of infection and malignan-
cy against the possible benefits of combination treatment
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The use of more than two immunomodulators is asso-
ciated with a higher risk of opportunistic infections76
and the use of thiopurines is associated with a 5-fold in-
crease in the risk of lymphoma.77 Of particular concern
has been the observation of universally fatal HSTCL in pa-
tients treated with the combination of azathioprine and
infliximab.78
In summary, there is no clear evidence to guide the precise
timing of withdrawal of concomitant immunomodulators;
however continuation of immunomodulators is reasonable
after commencement of a biological agent for refractory
disease.
Question 7: Immunomodulator failure
7. If the immunomodulator does not work, what should the
approach be? Increase the dosage? Add corticosteroids?
Change the immunomodulator? Move to an anti-TNF agent?
1. In any patient with a flare or symptoms rule out infections
and complications.
2. In a patient on standard weight-based dose of thiopurines
there is no evidence for dose increase.
3. Anti-TNF therapy can be the first consideration in patients
who have been on optimal immunomodulator therapy and lost
response.
4. If a patient shows intolerance or side effects to purine
metabolite immunomodulators, other immunomodulators
(methotrexate) or anti-TNF agents may be considered.
83% agreement after 2nd vote
Gastrointestinal infection is an important consideration
in the differential diagnosis of acute flares in patients with
IBD. It can precipitate a flare, or simply mimic the symptoms
(e.g. abdominal pain and diarrhoea). For this reason, it must
be ruled out in an immunosuppressed patient who had previ-
ously been in remission (based on opinion). In IBD patients
receiving an immunomodulator, most commonly azathio-
prine, there is no evidence to support increasing an already
optimised weight-based dose. On the contrary, it may in-
crease the risk of liver injury79 and myelosuppression, al-
though the latter is also influenced by underlying TPMT
activity.80
In patients with IBD with a flare of disease activity de-
spite a stable immunomodulator dose, existing evidence
strongly supports the addition of anti-TNF therapy. A
meta-analysis of 14 randomised, placebo-controlled trials
of luminal Crohn's disease, including 3995 patients (most
of whom had active disease and were already on immuno-
modulator therapy) treated with infliximab, adalimumab
or certolizumab, demonstrated efficacy in inducing re-
sponse and remission.81 In a further analysis of 21 studies
including 5356 individuals, anti-TNF therapy did not in-
crease the risk of death, malignancy or serious infection.81
As mentioned previously, the SONIC study has also shown
that combined use of infliximab and azathioprine resulted
in better remission rates in Crohn's disease than infliximab
alone, and that both the combination and infliximab alone
were superior to azathioprine alone.66 However, increased
risk of lymphoma and tuberculosis, although only margin-
ally higher than with azathioprine use, should be discussed
with patients before initiating anti-TNF therapy.77,82Adequately designed studies of other immunomodulators
in patients failing thiopurine therapy are lacking. Two retro-
spective studies, published in abstract form only, suggest
that methotrexate may have a benefit in clinical response
and remission in Crohn's disease, but ultimately, many
patients go on to anti-TNF use.83,84 A retrospective
series of mycophenolate mofetil use in Crohn's disease pa-
tients failing on azathioprine suggests that, while it may
induce remission, its efficacy is limited by a high occurrence
of side effects.85 Overall, there is little evidence to support
switching immunomodulators in azathioprine failure.
In patients who demonstrate intolerance to azathioprine,
there is an argument for switching to other immunomodula-
tors. Retrospective studies of patients who could not toler-
ate azathioprine suggests that half or more will be able to
tolerate 6-MP and remain on it long term.86 Furthermore,
evidence from case-series and retrospective reviews sug-
gests that patients intolerant to thiopurines may achieve
remission with methotrexate and mycophenolate mofetil.
Finally, based on their well-established efficacy in the
treatment of IBD, anti-TNF agents (either alone, or in combi-
nation with another immunomodulator) should be an impor-
tant consideration in the azathioprine-intolerant patient.
Question 8: Flare-ups with immunomodulators or anti-TNFs
8. If a patient experiences flare-ups when receiving
immunomodulators or anti-TNF therapy, should
corticosteroids be added?
1. If a patient loses response to an anti-TNF agent,
optimisation of therapy should be considered before starting
corticosteroids
i. It is necessary to re-evaluate disease and confirm
inflammatory disease before optimising therapy
2. If a patient loses response to immunomodulator therapy,
optimisation of therapy and checking compliance should be
considered before considering corticosteroids. Avoid use of
corticosteroids when failing immunomodulator therapy where
possible
i. Switching to an anti-TNF does not usually require bridging
corticosteroids
ii. If corticosteroids are necessary (e.g. to switch between
immunomodulator therapies) dose should be tapered over a
period of weeks to limit exposure to their significant side
effects
77% agreement after 1st vote
The approach to patients failing immunomodulator thera-
py was addressed in the previous question. Here, the ap-
proach to IBD patients failing anti-TNF therapy is discussed.
However, with regard to immunomodulator therapy, it
should be reiterated that adding a course of corticosteroids
alone, when patients experience a flare on thiopurines, is
not recommended, and consideration must be given to start-
ing anti-TNF therapy. While there are no published data to
guide the use of corticosteroids in this circumstance, it is
often not necessary to give a corticosteroid course when ini-
tiating anti-TNF therapy, unless its initiation is going to be
significantly delayed and the patient urgently requires treat-
ment (i.e. hospitalised patients). As addressed previously,
prolonged corticosteroid use is associated with significant
side effects, beyond those of other immunomodulators.
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failing on immunomodulator therapy only increases the risk
of side effects and is generally not necessary when switching
to anti-TNF therapy.
Patients who experience worsening inflammatory activity
despite having previously had a good response on an anti-
TNF agent do pose a significant challenge for the gastroen-
terologist. Opinion suggests that it is important to rule out
underlying gastrointestinal infections, check compliance
with therapy, and verify active disease by laboratory, endo-
scopic and histological investigations. Once active inflamma-
tory disease has been verified, there is evidence to suggest
that doubling the dose of the anti-TNF agent, increasing its
frequency of administration, or providing a re-induction reg-
imen can regain response in these patients.87–90 In addition,
randomised studies and a systematic review suggest that ap-
proximately 30% of patients failing one anti-TNF agent will
achieve sustained remission by switching to another anti-
TNF agent.91–94 Corticosteroid bridging therapy was not
employed in any of these studies. There is no direct evidence
that corticosteroid use when switching anti-TNF agents im-
proves outcome, and they should not be routinely employed
when switching anti-TNF agents or when altering anti-TNF
dose or administration schedule. If given, corticosteroids
should be limited to a tapering regimen lasting at most
12 weeks, as described in earlier questions.
Question 9: Risk of cancer and infection
9. What are the risks of cancers (all kinds) and infections
associated with the short-, mid- and long-term use of
immunomodulators and corticosteroids?
1. Although absolute risk is very low, combined use of
thiopurines and anti-TNF agents increase the risk of
lymphoproliferative disorders.
2. The risk of other malignancies (solid organ tumours)
associated with thiopurines and combined thiopurine and
anti-TNF therapy still needs to be proven, although there is an
increased risk of non-melanoma skin cancer and yearly skin
examination should be routinely practised.
3. In most cases, the absolute risk of malignancy remains low;
however, the impact of additional risk factors such as young
age, Epstein Barr virus status, older age (N65 years),
malnutrition, and history of previous malignancy should be
taken into account.
4. Immunomodulators and/or corticosteroids and anti-TNF
agents are associated with an increased risk of infection.
Long-term corticosteroids, but not other immunomodulators,
appear to increase risk of perioperative infection. The risk of
infection is further increased in older patients, and in patients
with co-morbidities and/or malnutrition.
5. The risk of infection in patients with IBD is likely to increase
with the number of immunomodulator agents that are used
concomitantly, particularly with use of concomitant
corticosteroids.
6. The long-term concomitant use of thiopurine and anti-TNF
therapy should be carefully considered. In adolescents and
young (b35 years) patients (particularly males), combined
thiopurine and anti-TNF therapy should be used with caution
because of the small risk of HSTCL.
90% agreement after 1st vote3.1. Lymphoproliferative disorders
The risk of lymphoproliferative disorders has become a major
concern for clinicians managing patients with IBD. However,
it is difficult to distinguish the possible responsibility of immu-
nomodulator therapy from the background risk due to the
inflammatory disorder itself and other confounding factors
such as disease severity and disease duration.95 Since thiopur-
ines are cytotoxic for natural killer and cytotoxic T-cells, their
use might be associated with a proliferation of Epstein–Barr
virus in infected and immortalised B-cells, eventually leading
to a lymphoproliferative disorder. A meta-analysis has shown
a pooled relative risk of 4.18 for the development of a lympho-
ma in patients receiving azathioprine or 6-MP compared with
the general population.96 In a recent French prospective ob-
servational cohort study including 19,486 patients with IBD,
lymphoproliferative disorders were observed more frequently
in patients receiving thiopurines compared with patients who
had never received these drugs (hazard ratio 5.28).77 Similar
data were observed in a UK population-based case–control
study.97 Whether the risk of lymphoproliferative disorder is
also increased in patients with IBD receiving methotrexate
is currently unknown, mainly due to its restricted use in IBD.
A specific lymphoproliferative disorder which has re-
ceived great attention in the past 5 years is HSTCL. Since
the introduction of infliximab, several cases of fatal HSTCL
have been described, mainly in young males.98 The majority
of these patients were receiving concomitant immunomodu-
lator agents, but some cases of HSTCL have been described
in patients with IBD under thiopurine analogues alone. A pol-
icy of minimising the concomitant use of thiopurine and bio-
logical agents in patients with IBD, particularly in the
apparently high-risk group of adolescents and young (male)
adults, is often advocated.95
3.2. Solid organ cancers
In the UK population-based case–control study mentioned
above, overall cancer risk was not increased in patients re-
ceiving azathioprine.97 However, more recently, thiopurine
analogues have been associated with the development of
non-melanoma skin cancer in patients with IBD.99 The inci-
dence of non-melanoma skin cancer in an American case–
control trial was higher among patients with IBD compared
with controls, and both recent and persistent thiopurine
use were associated with non-melanoma skin cancer.99 Al-
though not evidence-based, yearly skin examination by a
trained dermatologist seems mandatory.
3.3. Infections
In the Crohn's Therapy, Resource, Evaluation, and Assess-
ment Tool (TREAT) registry, 6290 patients with Crohn's
disease were prospectively followed in several North Ameri-
can centres.22 The majority of patients were treated with
immunomodulators (azathioprine, 6-MP or methotrexate).
The study found that corticosteroids were independently as-
sociated with the development of serious infections, but
there was no association with immunomodulators.
In a case–control study, including 100 consecutive pa-
tients with IBD with an opportunistic infection and 200
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and infliximab was associated with significantly increased
odds for opportunistic infections, with a considerably higher
risk associated with the use of two or three agents versus
one agent.100 The type of infection was different for the
three drugs and the absolute number of events was relative-
ly low. However, the use of concomitant corticosteroids in
particular increased the infection risk. In a Belgian single-
centre cohort study, concomitant treatment with cortico-
steroids was the only independent risk factor for infec-
tions.101 The interim analysis of the European National
Crohn's Observational Registry (ENCORE) showed a similar in-
creased risk for serious infections in patients under
prednisone.102
Finally, a recent meta-analysis, including seven observa-
tional studies involving 1532 patients with IBD, showed an in-
creased risk of postoperative infectious complications in
patients receiving corticosteroids.103 In a Belgian cohort
evaluating complications after pouch surgery, a moderate-
to-high dose of corticosteroids (≥20 mg methylprednisolone
for ≥2 months) was associated with postoperative infectious
complications, while the use of infliximab was not.104
Question 10: Optimal safety monitoring
10. What is the optimal safety monitoring (clinical, laboratory,
radiological) of patients receiving immunomodulators or
corticosteroids? How often?
1. There may be severe myelosuppression in all patients
receiving immunomodulator therapy
i. TPMT analysis (where readily available) may identify
those with low TPMT activity at greatest risk of severe
haematological complications
ii. Also consider a gradual dose increase starting with
1 mg/kg azathioprine (0.5 mg/kg mercaptopurine), with
regular (1–2 weekly) blood count monitoring until target
dose is achieved
iii. Patients should be informed about the risks (including
pancreatitis) and proper diagnostic steps should be
performed when appropriate
2. In addition to clinical safety monitoring, carry out regular
monitoring of full blood count and liver function tests in all
patients receiving thiopurines and methotrexate. For example,
before initiating therapy, every 1–2 weeks during the first
month, monthly up to 3 months, and then every 3 months
i. In patients with persistently elevated liver function tests
under methotrexate therapy, methotrexate should be
stopped and liver biopsy considered (American College of
Rheumatology guidelines105)
3. In addition, take the following measures in patients initiating
or taking immunomodulators:
i. Follow guidelines for the prevention of opportunistic
infections in IBD (e.g. ECCO consensus106 andUS guidelines107)
− Vaccinations
− Pap smear for females receiving thiopurines
ii. Solar protection for patients receiving thiopurines, including
regular dermatological screening for long-term thiopurine use
iii. Seek urgent medical advice for clinical signs of fever, severe
infections, unexplained symptoms, including neurological
4. Patients receiving high doses of corticosteroids should alsoundergo clinical monitoring, paying particular attention to the
risk of opportunistic infection, intra-abdominal abscesses,
perforations, hypertension, diabetes (or worsening diabetes) and
ophthalmological complications (glaucoma)
i. There is no evidence to support a particular method of
monitoring
ii. Calcium and vitamin D supplementation should be
considered
97% agreement after 2nd vote3.4. Optimal safety monitoring of patients receiving
immunomodulators
Thiopurine-related adverse events occur in 5–40% of patients
in both a dose-dependent and a dose-independent, idiosyn-
cratic manner. These adverse events lead to therapy discon-
tinuation in up to 26% of treated patients.108 Approximately
89% of the general population has wild-type TPMT, which is as-
sociated with normal or high TPMT enzyme activity, while 10%
are heterozygous and display intermediate activity.109 Most
importantly, 0.3% of the general population are homozygous
for low-activity TPMT alleles and display no detectable TPMT
activity, which causes 6-MP to be preferentially metabolised
to produce high concentrations of 6-thioguanine, which then
leads to bone marrow suppression.
Genotyping the three most common single nucleotide
polymorphisms (G238C for TPMT*2, G460A and A719G for
TPMT*3A, TPMT*3B and TPMT*3C) or measuring the enzyme
activity are two methods for predicting the risk of haemato-
poietic toxicity. TPMT enzymatic activity can be measured in
red blood cells with a radiochemical or high-performance
liquid chromatography assay.110 There is no consensus yet
that TPMT genotype or phenotype should be measured be-
fore starting azathioprine or 6-MP treatment in patients
with IBD, since 73% of patients with severe bone marrow sup-
pression do not carry a TPMT mutation.111
Some investigators suggest that thiopurine agents should
be avoided entirely in patients with low TPMT activity (het-
erozygotes); however, it seems that most patients with low
TPMT activity can be treated safely with 50% of the normal
azathioprine or 6-MP dose provided they are closely moni-
tored.112 Homozygous or compound heterozygous patients
with no TPMT activity should not receive the drug. Impor-
tantly, patients with no TPMT mutations or normal TPMT
activity, who can receive full dose azathioprine or 6-MP
from the start, also require regular full blood count
monitoring.110
Nodular regenerative hyperplasia is a rare but potentially
severe complication of azathioprine in patients with IBD. A
systematic survey of patients with IBD followed at 11 Euro-
pean centres identified 37 cases of nodular regenerative
hyperplasia, of whom 14 developed complications of portal
hypertension.113 In a US study, 33% of asymptomatic pa-
tients with IBD treated with 6-thioguanine and with normal
biological results were shown to have nodular regenerative
hyperplasia at liver biopsy.114 Clinicians should be aware of
this complication and should monitor liver function tests
and platelet counts closely.113
In patients receiving methotrexate, measurement of full
blood count and liver function tests are advisable before
and within 4 weeks of starting therapy, then monthly to
Table 1 Key programme outcomes.
Do… Do not…
Identify patients with poor
prognosis
Intervene early with
immunomodulators and
optimise dosing early
Make corticosteroid-free Do not use prolonged or
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plied for patients receiving thiopurines, although no evi-
dence-based data are available.
Patients initiating or taking immunomodulators should re-
ceive proper vaccinations and Pap smears.106 Furthermore,
solar protection is warranted in patients receiving thiopur-
ines. Finally, patients should seek urgent medical advice
for clinical signs of fever, severe infections, and unexplained
symptoms including neurological symptoms.remission a goal repetitive courses of
corticosteroids or
underestimate
corticosteroid toxicity
Achieve a balance between
clinical benefit and safety
when intensifying or
prolonging therapy or
combining different agents
Reassess patients at
appropriate time points
(prednisone at 2–4 weeks;
azathioprine 10–12 weeks)
Do not prolong the use of
azathioprine at standard
doses if full remission is
not achieved
Treat beyond symptoms
(biomarkers, mucosal
healing)3.5. Optimal safety monitoring of patients receiving
corticosteroids
Patients with IBD, especially Crohn's disease, are at in-
creased risk of osteopenia and osteoporosis compared with
the general population.115 Several factors have been impli-
cated in the high rate of osteopenia and osteoporosis in
these patients, including corticosteroid use, relative malnu-
trition, and the presence of a chronic inflammatory state.
Therefore, calcium and vitamin D supplementation should
be considered. Particular attention towards intra-abdominal
abscesses, perforation, hypertension, diabetes and ophthal-
mological complications is warranted. However, there is no
evidence to support a particular method of monitoring.4. Conclusions
Key strengths of the IBD Ahead 2010 programme were that it
provided extensive research into the everyday problems
faced by practising gastroenterologists, conducted a com-
prehensive evaluation of the evidence base, and supplied
practical answers based on both evidence and the experi-
ence of approximately 600 gastroenterologists from 36 coun-
tries. Overall, the programme found that many doctors who
manage patients with Crohn's disease lack evidence about
basic aspects of corticosteroid and immunomodulator use
such as dosage, timing and duration of therapy, safety and
choice of drug or regimen, including when to switch agent.
In addition, they have questions about more general aspects
of the management of Crohn's disease, including the most
appropriate ways to define and monitor treatment efficacy
or lack of response. There are considerable variations in clin-
ical practice, as has been observed previously.116
Despite these differences, the gastroenterologists in-
volved in discussions to provide answers to the questions
were able to reach broad agreement on practically-based an-
swers. Key outcomes from the programme (Table 1) included
the importance of identifying patients with a poor prognosis
and the need to intervene early with an optimal dose of immu-
nomodulators. There was clear agreement that corticosteroid-
free remission is an important goal and that corticosteroid
toxicity means that prolonged or repetitive courses must be
avoided. The importance of achieving a balance between clin-
ical benefit and safety when intensifying or prolonging therapy
or combining different agents was another key point. The need
to re-assess patients at appropriate time points and change
therapy or dose if required was also highlighted. Finally, gas-
troenterologists also recognised the value of moving towards
treatment beyond symptoms and considering the role of muco-
sal healing and use of biomarkers.It must be highlighted that this programme was not
intended to provide formal guidance on the management
of Crohn's disease, and in particular, it cannot supplant
existing national and international guidelines. The pro-
gramme had limitations. Although answers were voted
upon using a recognised methodology, consolidation of the
feedback into the final answers was achieved mainly through
informal discussion rather than by formal consensus
methods. Many issues highlighted in the market research
phase could not be taken forward to later stages of the pro-
gramme. The design of the programme allowed incorpora-
tion of personal experience into development of the
answers; thus the answers were not purely evidence-based.
This could be regarded as both a strength and a weakness.
In summary, few high-quality data on conventional thera-
pies exist, and many questions remain unanswered. However,
data are becoming available on new treatment objectives
which will perhaps lead to a better consensus on these issues
in the future. We hope that this educational programme will
go some way towards providing practical answers to the
many unanswered questions.
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